Lundbeckfond Invest A/S's Form 4 filing
Lexeo Therapeutics, Inc.LXEO · filed Nov 9, 2023
- Accession no.
- 0001209191-23-054907
- Filed
- Nov 9, 2023
- Trade date
- Nov 7, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $2.50M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lundbeckfond Invest A/SCIK 0001591046 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2023 | Common Stock | CConversionAcquired | +1,321,474 | –F1 | – | 1,321,474 | Direct | |
| Nov 7, 2023 | Common Stock | CConversionAcquired | +287,213 | –F2 | – | 1,608,687 | Direct | |
| Nov 7, 2023 | Common Stock | PPurchaseAcquired | +227,272 | $11.00 | +$2,499,992 | 1,835,959 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
- F2
Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.